
BOTHELL, Washington--CellPro, Incorporated has received FDA approval for label expansion of the company’s Ceprate SC Stem Cell Concentration System to include the processing of peripheral blood progenitor cells (PBPCs) to obtain a CD34+ cell enriched population for use as hematopoietic support after myeloablative chemotherapy in patients with CD34-negative tumors.
